{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-22-000101","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2022-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.716357+00:00","generated_at":"2026-06-23T17:07:07.608163+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exelixis files second patent infringement suit against Teva over generic CABOMETYX","bullets":["Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.","Teva filed ANDA with Paragraph IV certification; Exelixis seeks injunction and FDA approval delay until patent expires Feb 10, 2032.","This is the second case; first case (2021) is stayed administratively, asserting three other patents expiring July 9, 2033.","No trial scheduled yet; Exelixis seeks equitable relief to block Teva's generic launch before patent expiration."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-22-000101","json":"https://secwatch.observer/filing/0000939767-22-000101.json","markdown":"https://secwatch.observer/filing/0000939767-22-000101.md","text":"https://secwatch.observer/filing/0000939767-22-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/0000939767-22-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/exel-20220902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:07:07.608163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}